Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2013-11-30
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protective Immune Mechanisms in Alcoholic Hepatitis
NCT01918462
Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease
NCT00610597
S100A8/A9 and Innate Immunity in Liver Disease
NCT05793983
Role of CCL2 in Alcoholic Liver Diseases
NCT01128010
Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis
NCT02808663
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Alcohol is the most common cause of liver disease in the developed world and results in the death of 2.5 million people annually. It is a causal factor in more than 60 major types of diseases and injuries and approximately 4.5% of the global burden of disease and injury is attributable to alcohol. Acute alcoholic hepatitis (AAH) is perhaps the most florid form of ALD and the leading cause of mortality in these patients is the development of sepsis which occurs in up to 40% of these patients and has a mortality rate of 50%.
By gaining a better understanding of the relationship between elements of the immune system and the progression to severe alcoholic hepatitis, it will allow the formulation of more effective treatment strategies for this condition.
Patients who agree to participate in this study will have an extra 40mls of blood drawn for scientific studies at the same time as routine blood samples are taken as part of their ongoing care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients presented with severe alcoholic hepatitis with a Maddrey score (discriminant function) of \>32 (The Maddrey score uses various blood results on a patient to define the severity of alcoholic hepatitis e.g.bilirubin etc).
3. Ongoing abuse of alcohol (drinking in excess of 28 units/wk)
Exclusion Criteria
2. Patients with autoimmune liver disease.
3. Patients with metabolic liver disease.
4. Patients with significant psychiatric and/or neurological co-morbidity.
5. Hepatocellular carcinoma or other neoplastic disease
6. Pregnancy or breast feeding of infants.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mid and South Essex NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gavin Wright, MBBS MRCP
Role: PRINCIPAL_INVESTIGATOR
Basildon and Thurrock University Hospitals NHS FT
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Basildon Hospital
Basildon, Essex, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B663
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.